OIS XIII Speakers 2023

Maryam Mokhtarzadeh

By Jackie Wengrod | November 30, 2023

Maryam joined Regenxbio as Senior Director for Regulatory Strategy earlier this year building on her prior leadership experience at AbbVie as Medical Director of Clinical…

Read More

Leslie Patch, MD

By Jackie Wengrod | November 20, 2023
Read More

Jim Nevelos, FRSA, PhD

By Jackie Wengrod | November 20, 2023
Read More

Rael Mazansky, MD, MBA

By Jackie Wengrod | November 20, 2023
Read More

Annabel Samimy

By Jackie Wengrod | November 20, 2023
Read More

Nick Pliam, MD, PhD

By Jackie Wengrod | November 20, 2023

Dr. Nick Pliam joined Decheng Capital at its inception in 2011 and is based in its Menlo Park office. Trained as an orthopedic surgeon and…

Read More

Barbara Wirostko, MD, FARVO

By Jackie Wengrod | November 13, 2023

Barbara Wirostko MD, a serial entrepreneur, is the CMO and Co-founder of Qlaris Bio as well as Co-founder and Medical Advisor to MyEyes. As a…

Read More

Theresa Heah, MD, MBA

By Jackie Wengrod | November 2, 2023

Dr. Heah is an accomplished executive who brings over two decades of drug development and commercial experience, focused primarily in gene therapy and ophthalmology. She…

Read More

Tomas Navratil, PhD

By Jackie Wengrod | November 2, 2023

Dr. Navratil has served as our chief development officer since April 2022. He previously served as our senior vice president, research and development since joining…

Read More

Abla Creasey, PhD

By Jackie Wengrod | November 2, 2023

Abla Creasey is the Vice President of Therapeutics Development. In this capacity, she leads all programs in Translational and Clinical development, with a focus on…

Read More

Victor Chong, MD

By Jackie Wengrod | November 2, 2023

Retinal specialist with both extensive basic science training, clinical trial experience and drug development experience in Big Pharma. Main research interest is macular diseases, including…

Read More

Riad Sherif, MD

By Jackie Wengrod | November 2, 2023

Dr. Sherif joined Oculis as CEO in 2017 from Novartis where he served as Entrepreneur in Residence at the Novartis Venture Fund and since 2022,…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.